Drug Safety Research and Development, Worldwide Research and Development, Pfizer Inc., Cambridge, MA 02140, USA, Oligonucleotide Therapeutic Unit, Worldwide Research and Development, Pfizer Inc., Cambridge, MA 02139, USA and Attagene Inc., Morrisville, NC 27560, USA.
Nucleic Acids Res. 2014 Apr;42(8):4882-91. doi: 10.1093/nar/gku142. Epub 2014 Feb 18.
Fully phosphorothioate antisense oligonucleotides (ASOs) with locked nucleic acids (LNAs) improve target affinity, RNase H activation and stability. LNA modified ASOs can cause hepatotoxicity, and this risk is currently not fully understood. In vitro cytotoxicity screens have not been reliable predictors of hepatic toxicity in non-clinical testing; however, mice are considered to be a sensitive test species. To better understand the relationship between nucleotide sequence and hepatotoxicity, a structure-toxicity analysis was performed using results from 2 week repeated-dose-tolerability studies in mice administered LNA-modified ASOs. ASOs targeting human Apolipoprotien C3 (Apoc3), CREB (cAMP Response Element Binding Protein) Regulated Transcription Coactivator 2 (Crtc2) or Glucocorticoid Receptor (GR, NR3C1) were classified based upon the presence or absence of hepatotoxicity in mice. From these data, a random-decision forest-classification model generated from nucleotide sequence descriptors identified two trinucleotide motifs (TCC and TGC) that were present only in hepatotoxic sequences. We found that motif containing sequences were more likely to bind to hepatocellular proteins in vitro and increased P53 and NRF2 stress pathway activity in vivo. These results suggest in silico approaches can be utilized to establish structure-toxicity relationships of LNA-modified ASOs and decrease the likelihood of hepatotoxicity in preclinical testing.
全硫代磷酸酯反义寡核苷酸 (ASO) 与锁核酸 (LNA) 结合可提高靶标亲和力、核糖核酸酶 H 激活和稳定性。LNA 修饰的 ASO 可引起肝毒性,目前对此风险尚不完全了解。体外细胞毒性筛选对于非临床测试中的肝毒性并不是可靠的预测指标;然而,小鼠被认为是一种敏感的测试物种。为了更好地了解核苷酸序列与肝毒性之间的关系,对在接受 LNA 修饰的 ASO 的小鼠中进行的为期 2 周的重复剂量耐受性研究的结果进行了结构毒性分析。针对人类载脂蛋白 C3 (Apoc3)、环磷酸腺苷反应元件结合蛋白 (CREB) 调节转录共激活因子 2 (Crtc2) 或糖皮质激素受体 (GR,NR3C1) 的 ASO 根据在小鼠中是否存在肝毒性进行分类。根据这些数据,来自核苷酸序列描述符的随机决策森林分类模型确定了仅存在于肝毒性序列中的两个三核苷酸基序(TCC 和 TGC)。我们发现,含有基序的序列更有可能在体外与肝细胞蛋白结合,并增加体内 P53 和 NRF2 应激途径的活性。这些结果表明,基于计算机的方法可用于建立 LNA 修饰的 ASO 的结构-毒性关系,并降低临床前测试中肝毒性的可能性。